| Dr Michelle Vargas, MD | |
|
230 Maple St Ste 1, Holyoke, MA 01040-5140 | |
| (413) 420-2200 | |
| (413) 539-9472 |
| Full Name | Dr Michelle Vargas |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 9 Years |
| Location | 230 Maple St Ste 1, Holyoke, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912389818 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 264668 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Holyoke Medical Center | Holyoke, MA | Hospital |
| Mercy Medical Ctr | Springfield, MA | Hospital |
| Baystate Medical Center | Springfield, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Holyoke Health Center Inc | 8527969302 | 36 |
News Archive
Researchers at Eastern Virginia Medical School's Strelitz Diabetes Center and the school's department of physiological sciences have published research showing a strong link between a large waistline and increased risk of Type 2 diabetes and cardiovascular disease.
Medicaid — which has been a political football between Washington and state capitols during the past decade — scored big in Tuesday's election.
Oxford Gene Technology, provider of innovative genetics research and biomarker solutions to advance molecular medicine, has produced a new, free-to-download whitepaper titled ‘When to use targeted resequencing — Choosing the right NGS method.'
There are three common drugs for advanced ovarian cancer: paclitaxel, cyclophosphamide, and topotecan. Like a shell game, if you pick the right drug a patient is likely to respond. And, unfortunately, picking the wrong drug can lead to treatment failure. As reported in this month's issue of the journal PLoS ONE, a University of Colorado Cancer Center and University of Virginia study used a sophisticated model of ovarian cancer genetics to match the right tumor with the right drug. Patients who were matched in this way lived an average 21 months longer than patients who were not matched.
An international team of researchers has provided further evidence to confirm the immunogenicity and efficacy of a recombinant adenovirus vaccine currently being tested in phase 3 trials for its ability to protect against infection with severe acute respiratory coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).
› Verified 2 days ago
| Entity Name | Holyoke Health Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740271022 PECOS PAC ID: 8527969302 Enrollment ID: O20040408000104 |
News Archive
Researchers at Eastern Virginia Medical School's Strelitz Diabetes Center and the school's department of physiological sciences have published research showing a strong link between a large waistline and increased risk of Type 2 diabetes and cardiovascular disease.
Medicaid — which has been a political football between Washington and state capitols during the past decade — scored big in Tuesday's election.
Oxford Gene Technology, provider of innovative genetics research and biomarker solutions to advance molecular medicine, has produced a new, free-to-download whitepaper titled ‘When to use targeted resequencing — Choosing the right NGS method.'
There are three common drugs for advanced ovarian cancer: paclitaxel, cyclophosphamide, and topotecan. Like a shell game, if you pick the right drug a patient is likely to respond. And, unfortunately, picking the wrong drug can lead to treatment failure. As reported in this month's issue of the journal PLoS ONE, a University of Colorado Cancer Center and University of Virginia study used a sophisticated model of ovarian cancer genetics to match the right tumor with the right drug. Patients who were matched in this way lived an average 21 months longer than patients who were not matched.
An international team of researchers has provided further evidence to confirm the immunogenicity and efficacy of a recombinant adenovirus vaccine currently being tested in phase 3 trials for its ability to protect against infection with severe acute respiratory coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michelle Vargas, MD 230 Maple St Ste 1, Holyoke, MA 01040-5140 Ph: (413) 420-2200 | Dr Michelle Vargas, MD 230 Maple St Ste 1, Holyoke, MA 01040-5140 Ph: (413) 420-2200 |
News Archive
Researchers at Eastern Virginia Medical School's Strelitz Diabetes Center and the school's department of physiological sciences have published research showing a strong link between a large waistline and increased risk of Type 2 diabetes and cardiovascular disease.
Medicaid — which has been a political football between Washington and state capitols during the past decade — scored big in Tuesday's election.
Oxford Gene Technology, provider of innovative genetics research and biomarker solutions to advance molecular medicine, has produced a new, free-to-download whitepaper titled ‘When to use targeted resequencing — Choosing the right NGS method.'
There are three common drugs for advanced ovarian cancer: paclitaxel, cyclophosphamide, and topotecan. Like a shell game, if you pick the right drug a patient is likely to respond. And, unfortunately, picking the wrong drug can lead to treatment failure. As reported in this month's issue of the journal PLoS ONE, a University of Colorado Cancer Center and University of Virginia study used a sophisticated model of ovarian cancer genetics to match the right tumor with the right drug. Patients who were matched in this way lived an average 21 months longer than patients who were not matched.
An international team of researchers has provided further evidence to confirm the immunogenicity and efficacy of a recombinant adenovirus vaccine currently being tested in phase 3 trials for its ability to protect against infection with severe acute respiratory coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).
› Verified 2 days ago
Dr. Andrew S Levin, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 10 Hospital Dr, Suite 307, Holyoke, MA 01040 Phone: 413-534-3244 Fax: 413-535-3297 | |
Stephanie Joanne Billings, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 230 Maple St, Holyoke Health Center, Holyoke, MA 01040 Phone: 413-420-2200 | |
Dr. Elizabeth Marie O Dair, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 230 Maple St, Holyoke, MA 01040 Phone: 413-420-2200 | |
Dr. Jennifer Anne Jurcsak, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 230 Maple St, Holyoke, MA 01040 Phone: 413-420-2200 Fax: 413-539-9535 | |
Thomas M Klepacki, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1221 Main Street, Western Regional/medical Examiner, Holyoke, MA 01040 Phone: 413-538-6213 | |
Ronald Loescher, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 230 Maple St, Holyoke, MA 01040 Phone: 413-420-2200 Fax: 413-420-2260 | |
Stephen John Levine, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1221 Main St, Suite 302, Holyoke, MA 01040 Phone: 413-536-5525 Fax: 413-533-4084 |